XORTX THERAPEUTICS XRTXF overview

● Type C Meeting Requested to Accelerate XRx-026 for Gout to NDA ● CALGARY, Alberta, Feb. 24, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces that it has submitted a Type C meeting request with the US Food and Drug Administration (the “FDA”) regarding the...

CALGARY, Alberta, Jan. 29, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces attendance and presentation at the Microcap Conference hosted by DealFlow Events on January 28 through 30, 2025 in Atlantic City, NJ. Attendance at this conference continues outreach to the...

CALGARY, Alberta, Jan. 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces the Company has changed its auditor from Smythe LLP, Chartered Professional Accountants (“Former Auditor”) to Davidson & Company LLP, Chartered Professional Accountants, (“Successor Auditor”)...

CALGARY, Alberta, Jan. 06, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces the launch of a new late stage program to treat gout. The new drug development program - XRx-026 - will focus on the treatment of individuals who have gout and are intolerant to allopurinol. With the clinical...

CALGARY, Alberta, Dec. 19, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Dr. Michael Bumby, a biotech/pharma industry veteran, as its Chief Financial Officer replacing James Fairbairn, the Company’s current Chief Financial Officer. Dr. Bumby, DVM, MBA, is currently a director and...

CALGARY, Alberta, Dec. 12, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce a presentation by Dr. Allen Davidoff at the Rare and Genetic Kidney Disease Summit, in Boston, Massachusetts at 10:30 am ET, Thursday December 12, 2024. The presentation entitled “ Autosomal...

● Health consequences of chronically high uric acid and xanthine oxidase in polycystic kidney disease in rats, mice and humans ● CALGARY, Alberta, Oct. 24, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the acceptance of an abstract submitted to the American...

CALGARY, Alberta, Oct. 18, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, today announced that it has closed its registered direct offering and concurrent private placement, announced on October 17, 2024, for the purchase and sale of 810,810 common shares (or pre-funded warrants in lieu...